H. Miao

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

I. Flinn, D. Miklos, C. Jacobson, 2023, Blood.

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

S. de Vos, C. Jacobson, S. Neelapu, 2023, Blood.